Titlebook: Immunotherapy of Hepatocellular Carcinoma; Tim F. Greten Book 2017 Springer International Publishing AG 2017 Hepatocellular carcinoma.live

不公開

Anti-VEGFR Therapy as a Partner for Immune-Based Therapy Approaches in HCC,ssive cell infiltration (M2-activated macrophages, T regulatory cells and myeloid-derived suppressor cells) and upregulation of immune checkpoints. These immunosuppressive cues lead to impaired effector CD8+ T lymphocyte infiltration and function, and ultimately to immune evasion. Reactivation of th

Coronary-Spasm

Glypican-3 as a Target for Immune Based Therapy in Hepatocellular Carcinoma, GPC3 as an emerging target in various investigational immunotherapies, with a focus on cancer vaccines, human or humanized antibodies, bispecific antibodies, immunotoxins, and chimeric antigen receptor (CAR) T cells. GPC3 peptide-based vaccines have been shown to prevent HCC recurrence after surger

fabricate

Immune Suppressor Mechanisms in HCC, relatively low or can even be discontinued in selected patients over time. Furthermore, the liver is showered with many antigens from the gastrointestinal tract delivered through the portal vein without causing active immune responses. In contrary, tumor-specific immune responses against tumors ari

Pruritus

Impact of Cytokines in Hepatocellular Carcinoma Initiation and Progression,n of many types of cancers, including hepatocellular carcinoma (HCC). Despite considerable progress in HCC diagnosis and improvement of the curative strategies, its incidence is still increasing in western countries and the prognosis of patients with advanced HCC remains in general very poor. Divers

Noctambulant

Notify